EcoR1 Capital, LLC: CENTESSA PHARMACEUTICALS PLC (CNTA): Quarterly 13F Position History
As of Q1 2026, EcoR1 Capital, LLC reported 6,000,000 shares of CENTESSA PHARMACEUTICALS PLC (CNTA), worth $238.3M and representing 10.2% of its 13F equity book. Quarter-over-quarter share count change: + 2,885,000 (+92.6%) . The position first appeared in Q2 2021 and has been disclosed across 20 13F-HR filings in Pactolio's tracked window.
- 6,000,000Shares Held (Latest Filing)
- $238.3MReported Market Value (Latest Filing)
- 10.2%Portfolio Weight (% of 13F Equity Book)
- +2,885,000Quarter-over-Quarter Share Change
- +$160.4MQuarter-over-Quarter Value Change
- 6,000,000Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 20 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 6,000,000 | +2,885,000 | +92.6% | $238.3M | 10.2% | $39.7 |
| Q4 2025 | 3,115,000 | +2,565,000 | +466.4% | $77.9M | 3.6% | $25.0 |
| Q3 2025 | 550,000 | +550,000 | — | $13.3M | 0.6% | $24.3 |
| Q2 2025 | 0 | 0 | — | $0 | 0.0% | — |
| Q1 2025 | 0 | 0 | — | $0 | 0.0% | — |
| Q4 2024 | 0 | 3,223,851 | -100.0% | $0 | 0.0% | — |
| Q3 2024 | 3,223,851 | 2,490,553 | -43.6% | $51.5M | 1.8% | $16.0 |
| Q2 2024 | 5,714,404 | +95,625 | +1.7% | $51.6M | 1.6% | $9.0 |
| Q1 2024 | 5,618,779 | 0 | — | $63.5M | 1.6% | $11.3 |
| Q4 2023 | 5,618,779 | 0 | — | $44.7M | 1.2% | $8.0 |
| Q3 2023 | 5,618,779 | 0 | — | $36.4M | 1.2% | $6.5 |
| Q2 2023 | 5,618,779 | 0 | — | $34.8M | 0.9% | $6.2 |
| Q1 2023 | 5,618,779 | +386,500 | +7.4% | $21.6M | 0.7% | $3.9 |
| Q4 2022 | 5,232,279 | +1,995,927 | +61.7% | $16.2M | 0.5% | $3.1 |
| Q3 2022 | 3,236,352 | +2,944,032 | +1007.1% | $13.0M | 0.4% | $4.0 |
| Q2 2022 | 292,320 | 162,225 | -35.7% | $1.4M | 0.0% | $4.9 |
| Q1 2022 | 454,545 | 427,631 | -48.5% | $4.1M | 0.1% | $9.0 |
| Q4 2021 | 882,176 | +127,631 | +16.9% | $9.9M | 0.3% | $11.3 |
| Q3 2021 | 754,545 | 0 | — | $12.6M | 0.4% | $16.7 |
| Q2 2021 | 754,545 | — | — | $16.8M | 0.6% | $22.2 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did EcoR1 Capital, LLC first disclose a CNTA position in 13F-HR filings?
EcoR1 Capital, LLC first reported CENTESSA PHARMACEUTICALS PLC (CNTA) on its 13F-HR filing for the period ending 2021-06-30 (Q2 2021). The position has appeared on 20 reported quarters within Pactolio's tracked window.
What was EcoR1 Capital, LLC's most recent quarter-over-quarter share-count change in CNTA?
Between Q4 2025 and Q1 2026, EcoR1 Capital, LLC added 2,885,000 shares of CNTA (+92.6%), bringing the total reported position to 6,000,000 shares at a market value of $238.3M.
Does the implied price-per-share represent EcoR1 Capital, LLC's cost basis in CNTA?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.